Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
暂无分享,去创建一个
P. Gaulard | G. Salles | A. Rahmouni | T. Petrella | H. Tilly | C. Sebban | N. Mounier | C. Haioun | R. Delarue | R. Casasnovas | D. Canioni | A. Sonet | P. Beaussart | S. Castaigne | S. Bologna | T. El Gnaoui
[1] E. Giné,et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] N. Schmitz,et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Gisselbrecht,et al. Relapses, treatments and new drugs. , 2012, Best practice & research. Clinical haematology.
[4] T. Habermann,et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.
[5] Scott E. Smith,et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Gisselbrecht,et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. , 2010, Clinical lymphoma, myeloma & leukemia.
[7] C. Haioun,et al. Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). , 2010 .
[8] E. Giné,et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Iannitto,et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma , 2009, Cancer Chemotherapy and Pharmacology.
[10] C. Copie-Bergman,et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J. Vose,et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. Russo,et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Jeffrey W. Clark,et al. Gemcitabine‐associated thrombotic microangiopathy , 2004, Cancer.
[14] A. Zelenetz,et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.
[15] R. Stahel,et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[17] A. Norman,et al. An oxaliplatin‐based chemotherapy in patients with relapsed or refractory intermediate and high‐grade non‐Hodgkin's lymphoma , 2001, British journal of haematology.
[18] B. Debuire,et al. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] E. Raymond,et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.
[21] J. Benichou,et al. Analysis of phase II clinical trials in haematology and oncology: comparison of the triangular test to the usual methods. , 1991, Statistics in medicine.
[22] W. Hryniuk,et al. The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.